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Abstract
Introduction: The management of patients with high-risk features 
after radical prostatectomy (RP) is controversial. Level 1 evidence 
demonstrates that adjuvant radiation therapy (RT) improves survival 
compared to no treatment; however, it may overtreat up to 30% of 
patients, as randomized clinical trials (RCTs) using salvage RT on 
observation arms failed to reveal a survival advantage of adjuvant 
RT. We, therefore, sought to determine the current view of adjuvant 
vs. salvage RT among North American genitourinary (GU) radiation 
oncology experts.
Methods: A survey was distributed to 88 practicing North American 
GU physicians serving on decision-making committees of coopera-
tive group research organizations. Questions pertained to opin-
ions regarding adjuvant vs. salvage RT for this patient population. 
Treatment recommendations were correlated with practice patterns 
using Fisher’s exact test.
Results: Forty-two of 88 radiation oncologists completed the survey; 
23 (54.8%) recommended adjuvant RT and 19 (45.2%) recom-
mended salvage RT. Recommendation of active surveillance for 
Gleason 3+4 disease was a significant predictor of salvage RT rec-
ommendation (p=0.034), and monthly patient volume approached 
significance for recommendation of adjuvant over salvage RT; those 
seeing <15 patients/month trended towards recommending adju-
vant over salvage RT (p=0.062). No other demographic factors 
approached significance.
Conclusions: There is dramatic polarization among North American 
GU experts regarding optimal management of patients with high-
risk features after RP. Ongoing RCTs will determine whether adju-
vant RT improves survival over salvage RT. Until then, the almost 
50/50 division seen from this analysis should encourage practicing 
clinicians to discuss the ambiguity with their patients.
Introduction
Three randomized clinical trials (RCTs) have established the 
role of adjuvant radiation therapy (RT).1-3 SWOG 8794 revealed 
a survival advantage when patients who received adjuvant RT 
were compared to patients who were followed clinically with 
no salvage RT option even in the setting of prostate-specific 
antigen (PSA) failure.1 The other two trials — EORTC 22911 
and ARO 96/02 —failed to reveal an overall survival advan-
tage, likely due to the protocol stipulation of allowed or rec-
ommended salvage RT in men randomized to observation in 
case of biochemical failure.2-3 Moreover, all three trials have 
shown a 10-year biochemical progression-free survival rate 
of 26–41% in the observation arm, arguing that a third of 
patients with high-risk features after radical prostatectomy (RP) 
will never develop biochemical failure and, therefore, would 
receive unnecessary overtreatment with pelvic radiotherapy.4-6 
Two large, modern randomized trials (RAVES, RADICALS) are 
underway to help physicians determine if adjuvant RT has any 
advantage over initial observation and early salvage RT, but 
until results are published, this topic remains highly controver-
sial.7,8 We sought to determine the current view of adjuvant vs. 
salvage RT among North American genitourinary (GU) radia-
tion oncology experts due to their influence in shaping clinical 
trials and national guidelines. 
Methods
Survey design and deployment
The survey was designed to assess the opinion of GU experts 
on the preferred management of a hypothetical patient with 
a high-risk feature (extracapsular extension) following RP for 
prostate cancer — adjuvant RT or observation with early 
salvage RT only if PSA rises. A copy of the survey is shown 
in Appendix 1. The study was approved by the institutional 
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review board and electronically sent in November 2016 to 
88 North American GU oncology physicians, who serve 
on cooperative group research organizations such as NRG 
Oncology. The survey was designed and hosted by Research 
Electronic Data Capture (REDCap).9 
Statistical analysis
Based on responses, participants were categorized as sup-
porters of either adjuvant RT or salvage RT for men with 
high-risk features following RP. Treatment recommendations 
were correlated with practice patterns using Fisher’s exact test.
Results
Forty-two of the 88 radiation oncologists completed the sur-
vey, of whom 23 (54.8%) recommended adjuvant RT after 
RP; the remaining 19 (45.2%) recommended observation 
with early salvage RT if PSA rises (Fig. 1). 
No demographic factors (years in practice, geographic 
location of residency, geographic location of practice, month-
ly patient volume, practice type) were found to correlate with 
treatment recommendation. When we analyzed for associa-
tion with other treatment recommendations for men with 
prostate cancer, only recommendation of active surveillance 
for Gleason 3+4 disease was a significant predictor of recom-
mending salvage RT following RP for disease with high-risk 
features (p=0.034) (Table 1). No other treatment recommen-
dations (active surveillance recommendation for Gleason 6 
disease, first choice treatment preference for low-risk prostate 
cancer, brachytherapy boost for high-risk disease, consider-
ation of stereotactic body RT for oligometastatic disease, elec-
tive pelvic lymph node coverage, support for incorporation 
of advanced imaging modalities in standard practice) were 
significant. Monthly patient volume approached significance 
for recommendation of adjuvant RT over salvage RT; respon-
dents who see fewer than 15 patients per month were more 
likely to endorse adjuvant RT over salvage RT (p=0.062).
Discussion
Although biochemical control of prostate cancer with high-
risk features following RP (extracapsular extension, seminal 
vesicle invasion, and/or positive surgical margins) has indis-
putably been shown to be improved by adjuvant RT in three 
RCTs, only one of these trials has shown an improvement in 
overall survival — when patients randomized to observation 
were not offered salvage RT in case of biochemical progres-
sion.1-6 The other two trials recommended and stipulated 
salvage RT on observation arm and failed to show a survival 
advantage to upfront intervention with adjuvant pelvic RT. 
Moreover, in all three trials, a third of patients on observation 
arm never experienced biochemical failure on observation 
arms, despite having high-risk features after RP. The 2017 
National Comprehensive Cancer Network (NCCN) guide-
lines delineate indications for adjuvant RT as “pT3 disease, 
positive margin(s), Gleason score 8–10, or seminal vesicle 
involvement” and that “evidence supports offering adjuvant/
salvage RT in most men with adverse pathological features or 
detectable PSA and no evidence of disseminated disease.”10
The results of our study indicate that for men with high-
risk features after RP, North American GU experts who are 
more likely to recommend salvage RT are also those who are 
more likely to recommend active surveillance for Gleason 
3+4 disease. This intuitively makes sense, as physicians who 
are more comfortable with initiation observation of patients 
with intermediate-risk prostate cancer (established by the 
recently published ProtecT randomized trial11) should also 
feel as comfortable with initial observation of men with high-
risk features after RP. Although no other demographic factor 
proved significant, the trend of experts seeing fewer than 
15 patients/month being more likely to recommend adju-
vant RT over salvage RT is interesting and deserves further 
investigation; perhaps high-volume experts are more likely 
to believe in salvage RT than their low-volume counterparts. 
It is our hope that ongoing phase 3 RCTs in this arena, such 
as the Radiotherapy – Adjuvant vs. Early Salvage (RAVES) 
and RADICALS trials, will shed more light on adjuvant vs. 
early salvage RT.7-8 
Our study shares the limitations of the survey from which 
it is derived: a relatively small sample size, inability to cap-
ture a full range of options due to multiple-choice format, 
and a lack of granularity in addressing the socioeconomic 
and racial demographic of patients, the latter of which may 
impact the applicability of RCTs comprised of inadequately 
low non-White patient participation.12,13 
Conclusion
There is currently a nearly even split between radiation 
oncology experts in North America recommending adjuvant 
vs. salvage RT for patients with high-risk features after RP 
Fig. 1. Default recommendation for men with high-risk features after radical 
prostatectomy for prostate cancer among North American genitourinary 
oncology expert radiation oncologists. RT: radiation therapy.
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for prostate cancer. Ongoing, large, randomized trials will 
determine whether adjuvant therapy offers a survival advan-
tage over salvage RT. Until then, the almost 50/50 division 
seen among leading GU experts, according to this analysis, 
should help practicing clinicians discuss the ambiguity with 
their patients. National care and reimbursement policies may 
also influence the accepted standard of care.
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Table 1: Association between clinical practice recommendations and choice of adjuvant RT vs. observation with salvage RT 
for high-risk prostate adenocarcinoma following radical prostatectomy
Clinical demographic Clinical practice variable Adjuvant RT after radical 
prostatectomy
Observation with 
early salvage RT
p
Monthly patient volume Fewer than 15 11 (47.8%) 3 (15.8%) 0.062
15 or more patients 12 (52.2%) 16 (84.2%)
Active surveillance recommendation for 
Gleason 6 disease
Yes
No
21 (52.5%)
2 (100%)
19 (47.5%)
0 (0%)
0.493
Active surveillance recommendation for 
Gleason 3+4 disease
Yes
No
1 (14.3%)
22 (62.9%)
6 (85.7%)
13 (37.1%)
0.034
SBRT for oligometastatic lesions Yes 16 (50%) 16 (50%) 0.305
No 7 (70%) 3 (30%)
Treatment of pelvic lymph nodes in localized 
high-risk prostate cancer
Rarely
Often
8 (61.5%)
15 (51.7%)
5 (38.5%)
14 (48.3%)
0.739
Treatment of high-risk prostate cancer EBRT+ADT
EBRT+ADT+
brachytherapy boost
13 (56.5%)
10 (52.6%)
10 (43.5%)
9 (47.4%)
1.0
Believer in advanced-imaging (Novel ligand-
based PET imaging)
Yes
No
14 (46.7%)
9 (72.7%)
16 (53.3%)
3 (27.3%)
0.173
First choice for treatment of Gleason 6 disease 
who desires intervention
Brachytherapy
EBRT
11 (52.4%)
4 (57.1%)
10 (47.6%)
3 (42.9%)
1.0
No preference 8 (57.1%) 6 (42.9%)
EBRT: external beam radiation therapy; PET: positron emission tomography; RT: radiation therapy; SBRT: stereotactic body radiation therapy.
